A Phase 3 interventional study of Valsartan and Amlodipine in Hypertension; Hypertrophy, Left Ventricular, sponsored by Novartis. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-05-11.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 98th largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 79th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is close to the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 165th largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2007, is one of 108 in phase 3, and was the 119th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of amlodipine plus valsartan in patients with hypertension and left ventricular hypertrophy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
Drug: Valsartan · Drug: Amlodipine
Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
Drug: Hydrochlorothiazide · Drug: Losartan
160 mg film coated tablets taken orally once daily in the morning.
5 mg or 10 mg tablets taken orally once daily in the morning.
12.5 mg or 25 mg tablets taken orally once daily in the morning.
100 mg tablets taken orally once daily in the morning.
Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)
Time frame: Baseline to week 52
Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI
Time frame: Baseline to week 52
Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI
Time frame: Baseline to week 52
Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI
Time frame: Baseline to week 52
Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI
Ejection fraction is a measurement of the percentage of blood that is pumped out of a filled ventricle with each heartbeat.
Time frame: Baseline to week 52
Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI
Time frame: Baseline to week 52
Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI
Time frame: Baseline to week 52
Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI
Time frame: Baseline to week 52
Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI
Time frame: Baseline to week 52
Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI
Time frame: Baseline to week 52
Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI
Time frame: Baseline to week 52
Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)
Time frame: Baseline to week 52
Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)
Time frame: Baseline to week 52
Percentage of Participants Achieving Target Blood Pressure at Week 52
Target blood pressure defined as having a mean sitting systolic blood pressure (MSSBP) \< 140 mm Hg and a mean sitting diastolic blood pressure (MSDBP) \< 90 mm Hg.
Time frame: Week 52
Percentage of Participants Who Experienced Adverse Events (AEs)
An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after obtaining informed consent even if the event was not considered to be related to study drug. Medical conditions/diseases present before obtaining informed consent were only considered adverse events if they worsened after study start. Abnormal laboratory values or test results constituted adverse events only if they induced clinical signs or symptoms, required study drug discontinuation or required therapy.
Time frame: Baseline to week 52
| Milestone | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Started | 43 | 47 |
| Completed | 36 | 38 |
| Not completed | 7 | 9 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Abnormal laboratory value(s) | 0 | 1 |
| Withdrew: Abnormal test procedure result(s) | 1 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 3 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Administrative problems | 0 | 1 |
| g/m˄2 | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI) | -7.1 ± 16.50 | -9.1 ± 18.89 |
| g/m˄2 | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI | -3.5 ± 7.4 | -4.4 ± 9.3 |
| mm | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI | -1.1 ± 1.5 | -0.6 ± 1.3 |
| mm | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI | -0.4 ± 1.1 | -0.3 ± 1.2 |
Ejection fraction is a measurement of the percentage of blood that is pumped out of a filled ventricle with each heartbeat.
| Percentage | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI | -0.8 ± 6.7 | -0.4 ± 5.9 |
| ml | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI | 0.1 ± 19.9 | -6.4 ± 22.9 |
| ml | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI | 0.0 ± 9.6 | -3.0 ± 11.2 |
| ml | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI | 0.4 ± 10.3 | -1.5 ± 10.3 |
| ml | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI | 0.2 ± 5.1 | -0.8 ± 5.1 |
| cm˄2 | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI | -0.6 ± 3.2 | -1.0 ± 4.5 |
| mm | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI | 0.1 ± 1.9 | -0.8 ± 1.6 |
| pg/ml | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP) | -4.5 ± 56.41 | -40.1 ± 74.09 |
| mg/l | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP) | 0.8 ± 6.09 | -2.1 ± 9.90 |
Target blood pressure defined as having a mean sitting systolic blood pressure (MSSBP) \< 140 mm Hg and a mean sitting diastolic blood pressure (MSDBP) \< 90 mm Hg.
| Percentage of participants | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Percentage of Participants Achieving Target Blood Pressure at Week 52 | 53.5 | 14.9 |
An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after obtaining informed consent even if the event was not considered to be related to study drug. Medical conditions/diseases present before obtaining informed consent were only considered adverse events if they worsened after study start. Abnormal laboratory values or test results constituted adverse events only if they induced clinical signs or symptoms, required study drug discontinuation or required therapy.
| Percentage of participants | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| Percentage of Participants Who Experienced Adverse Events (AEs) | 69.8 | 68.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan and Amlodipine | — | 2/43 (4.7%) | 15/43 (34.9%) |
| Losartan and HCTZ | — | 6/47 (12.8%) | 16/47 (34%) |
| Event | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| CORONARY ARTERY DISEASECardiac disorders | 1/43 | 0/47 |
| MYOCARDIAL INFARCTIONCardiac disorders | 1/43 | 0/47 |
| HYDROCELECongenital, familial and genetic disorders | 1/43 | 0/47 |
| CHOLECYSTITISHepatobiliary disorders | 1/43 | 0/47 |
| METASTATIC NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/43 | 0/47 |
| BRADYCARDIACardiac disorders | 0/43 | 1/47 |
| TACHYCARDIACardiac disorders | 0/43 | 1/47 |
| ABDOMINAL PAINGastrointestinal disorders | 0/43 | 1/47 |
| ANAL HAEMORRHAGEGastrointestinal disorders | 0/43 | 1/47 |
| DIARRHOEAGastrointestinal disorders | 0/43 | 1/47 |
| Event | Valsartan and Amlodipine | Losartan and HCTZ |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 3/43 | 7/47 |
| BACK PAINMusculoskeletal and connective tissue disorders | 5/43 | 2/47 |
| OEDEMA PERIPHERALGeneral disorders | 4/43 | 0/47 |
| DIARRHOEAGastrointestinal disorders | 1/43 | 4/47 |
| BRONCHITISInfections and infestations | 3/43 | 0/47 |
| NAUSEAGastrointestinal disorders | 1/43 | 3/47 |
| HEADACHENervous system disorders | 0/43 | 3/47 |
| ECZEMASkin and subcutaneous tissue disorders | 2/43 | 3/47 |
| Age Continuous(years) | Valsartan and Amlodipine | Losartan and HCTZ | Total |
|---|---|---|---|
| Mean | 58.2 ± 12.2 | 57.2 ± 10.9 | 57.7 ± 11.5 |
| Sex: Female, Male(Participants) | Valsartan and Amlodipine | Losartan and HCTZ | Total |
|---|---|---|---|
| Female | 12 | 13 | 25 |
| Male | 31 | 34 | 65 |
The record gives a start of Mar 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine